Citation Impact
Citing Papers
EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1–Independent and HIF-1–Dependent Mechanisms
2006
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy
2006
Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
2008
Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects
2004
Comprehensive genomic characterization of head and neck squamous cell carcinomas
2015 StandoutNature
Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
2003
ErbB Receptors: Directing Key Signaling Networks Throughout Life
2004
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation
2004
Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor
2007 StandoutNobel
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
2003
EGFR associated expression profiles vary with breast tumor subtype
2007
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
2001
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
ErbB-targeted therapeutic approaches in human cancer
2003
Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model
2002
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
2005
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
2009 Standout
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
The EGFR as a target for anticancer therapy—focus on cetuximab
2001
Comparing antibody and small-molecule therapies for cancer
2006
Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells
2003
Signal Transduction by the JNK Group of MAP Kinases
2000 Standout
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
ADP-Specific Sensors Enable Universal Assay of Protein Kinase Activity
2004
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Molecular mechanisms of drug resistance
2005
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex
2004 StandoutNobel
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines
2009
Lung Cancer
2008 Standout
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
The type III epidermal growth factor receptor mutation
2001
Proliferation, cell cycle and apoptosis in cancer
2001 StandoutNature
New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents
2002
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents
2000
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
2014 Standout
Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells
2002 StandoutNobel
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs
2003
Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor
2004 StandoutNobel
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Regulation of angiogenesis by hypoxia: role of the HIF system
2003 StandoutNobel
Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma
2004
Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer
2005
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF‐κB and AP‐1 activation and IL‐8 and VEGF expression in human head and neck squamous cell carcinoma lines
2002
Gefitinib — a novel targeted approach to treating cancer
2004
Targeting epidermal growth factor receptor—are we missing the mark?
2003
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
2007
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
2003
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
2002
‘Targeting’ the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC)
2004
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006 StandoutNature
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Challenges in the treatment of bladder cancer
2006
Gefitinib for non-small-cell lung cancer treatment
2011
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer
2007
Antitumor activity of the selective epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) Iressa® (ZD1839) in an EGFR‐expressing multidrug‐resistant cell line in vitro and in vivo
2001
Tumor Angiogenesis
2008 Standout
Advances in Malignant Mesothelioma
2005 Standout
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells
2003
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
2004
BindingDB Entry 50022499: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
2025
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Functional Nucleic Acid Sensors
2009 Standout
Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development
2007
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.
2003
Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib
2007
Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial
2002
Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
2000
Role of transforming growth factor-α in von Hippel– Lindau (VHL) −/− clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
2001
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
2001
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
2001 Standout
Role of transforming growth factor-α in von Hippel– Lindau\n (VHL)−/− clear cell renal carcinoma cell proliferation: A\n possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
2001
IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients
2005
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
2001
Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor
2005
Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition
2002
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
2002
Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screen
2008 StandoutNobel
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
2005
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer
2007
The Jun Kinase 2 Isoform Is Preferentially Required for Epidermal Growth Factor-Induced Transformation of Human A549 Lung Carcinoma Cells
1999
Molecular correlates of gefitinib responsiveness in human bladder cancer cells
2007
Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.
2003
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
2004
Cancer Genome Landscapes
2013 StandoutScience
Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy
2007
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
2003
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
2003
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.
2003
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
2002
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
2004 Standout
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
2004
Works of G Pomatico being referenced
Cooperative Inhibition of Renal Cancer Growth by Anti-Epidermal Growth Factor Receptor Antibody and Protein Kinase A Antisense Oligonucleotide
1998
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
2000
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
2000
Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells.
1999
Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.
1999